Patrick F Fogarty

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Large granular lymphocytic proliferation-associated cyclic thrombocytopenia
    Patrick F Fogarty
    Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA
    Am J Hematol 79:334-6. 2005
  2. ncbi Chronic immune thrombocytopenia in adults: epidemiology and clinical presentation
    Patrick F Fogarty
    Division of Hematology Oncology, Department of Medicine, University of California, San Francisco, 505 Parnassus Avenue, Room M 1286, San Francisco, CA 94143 1270, USA
    Hematol Oncol Clin North Am 23:1213-21. 2009
  3. ncbi Diagnosis and management of venous thromboembolism
    Tracy Minichiello
    Division of Hospital Medicine, Department of Medicine, University of California, San Francisco, CA 94143, USA
    Med Clin North Am 92:443-65, x. 2008
  4. ncbi High-dose cyclophosphamide with autologous lymphocyte-depleted peripheral blood stem cell (PBSC) support for treatment of refractory chronic autoimmune thrombocytopenia
    Richard D Huhn
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 101:71-7. 2003
  5. ncbi Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA
    Patrick F Fogarty
    Hematology Branch, National Heart, Lung, and Blood Institute, 10 Center Drive, MSC 1652, Bethesda, MD 20892-1652, USA
    Lancet 362:1628-30. 2003
  6. ncbi Resetting the immune system in immune thrombocytopenic purpura: immunoablative strategies
    Patrick F Fogarty
    Department of Laboratory Medicine, Hematology Service, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892 1508, USA
    Clin Adv Hematol Oncol 1:365-71. 2003

Detail Information

Publications6

  1. ncbi Large granular lymphocytic proliferation-associated cyclic thrombocytopenia
    Patrick F Fogarty
    Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA
    Am J Hematol 79:334-6. 2005
    ..LGLs decreased in response to treatment with cyclosporine-A (CsA), but the cycling of the platelet count continued. This is the first report of cyclic thrombocytopenia associated with a T-LGL lymphoproliferative disorder...
  2. ncbi Chronic immune thrombocytopenia in adults: epidemiology and clinical presentation
    Patrick F Fogarty
    Division of Hematology Oncology, Department of Medicine, University of California, San Francisco, 505 Parnassus Avenue, Room M 1286, San Francisco, CA 94143 1270, USA
    Hematol Oncol Clin North Am 23:1213-21. 2009
    ..More systematic analyses, with standardized definitions of cases and adequate duration of follow up, are needed...
  3. ncbi Diagnosis and management of venous thromboembolism
    Tracy Minichiello
    Division of Hospital Medicine, Department of Medicine, University of California, San Francisco, CA 94143, USA
    Med Clin North Am 92:443-65, x. 2008
    ..Although extremely effective, anticoagulants have a narrow therapeutic window; systems should be in place to reduce risk of adverse events associated with these agents...
  4. ncbi High-dose cyclophosphamide with autologous lymphocyte-depleted peripheral blood stem cell (PBSC) support for treatment of refractory chronic autoimmune thrombocytopenia
    Richard D Huhn
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 101:71-7. 2003
    ..This therapeutic approach is feasible for patients with severe chronic AITP, a substantial proportion of whom may obtain durable remissions. Larger controlled trials are recommended...
  5. ncbi Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA
    Patrick F Fogarty
    Hematology Branch, National Heart, Lung, and Blood Institute, 10 Center Drive, MSC 1652, Bethesda, MD 20892-1652, USA
    Lancet 362:1628-30. 2003
    ....
  6. ncbi Resetting the immune system in immune thrombocytopenic purpura: immunoablative strategies
    Patrick F Fogarty
    Department of Laboratory Medicine, Hematology Service, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892 1508, USA
    Clin Adv Hematol Oncol 1:365-71. 2003
    ..Approaches that will be discussed include conventional chemotherapy, high-dose chemotherapy with and without autologous stem cell support, and allogeneic transplantation...